Eyes On Elevance Health, Not UnitedHealth, As First To Report Earnings

Elevance Health's upcoming Q2 earnings report is highly anticipated as it will be the first major health insurer to disclose results amid widespread industry struggles with elevated medical costs, particularly in government-subsidized plans. Rivals like Centene, Molina Healthcare, UnitedHealth, Humana, and CVS Health have recently withdrawn guidance, lowered forecasts, or made executive changes due to rising expenses in ACA, Medicaid, and Medicare Advantage programs. While Elevance is perceived as more diversified with a strong commercial book and smaller Medicare Advantage exposure, its performance will offer critical insight into the broader sector's ability to manage cost pressures, given its millions of Medicaid and ACA enrollees.

Analysis

The U.S. health insurance sector is navigating significant headwinds from elevated medical costs, creating a clear divergence in outlook among major players. A wave of negative pre-announcements has set a cautious tone, with Centene withdrawing its 2025 financial guidance, Molina Healthcare lowering its 2024 earnings forecast, and UnitedHealth suspending its outlook amid rising costs in government-subsidized plans. These pressures, concentrated in Medicare Advantage, Medicaid, and ACA exchange products, have also impacted Humana and prompted CVS Health to exit the individual insurance market. Against this backdrop, Elevance Health's upcoming Q2 earnings report has become a critical bellwether, as it will be the first major insurer to report. Analysts view Elevance as potentially more resilient due to its diversified business model, where over half of its membership stems from commercial accounts. Furthermore, its Medicare Advantage business is notably smaller than that of peers like UnitedHealth, accounting for just 5% of its member mix. However, Elevance is not entirely insulated from sector-wide risks, maintaining significant exposure with over 8 million members in Medicaid plans and over 1 million in ACA coverage, making its cost management in these segments a key focus for investors.

Key Decisions for Investors

• Investors should closely monitor Elevance Health's medical loss ratio in its upcoming Q2 report, particularly within its Medicaid and ACA segments, to assess if its diversified model truly insulates it from the severe cost pressures that have led peers like Centene and Molina to cut guidance.
• The consistent negative guidance across the sector warrants a re-evaluation of portfolio exposure to insurers heavily concentrated in government programs; companies with a stronger commercial book, like Elevance, may offer a defensive position.
• Consider the potential for a relative value trade, such as being long Elevance Health (ELV) while being short a more vulnerable, government-focused peer, contingent on ELV's results confirming its operational resilience.